Project Grant R01CA312896
Award Date 6/5/26
Completion Date 5/31/31
Dollars Obligated $634K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23298, USA
Similar Awards
- Federal Grant Award Summary Virginia Commonwealth University received a $399,187 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 1, 2026 through June 30, 2028. The grant supports research into a novel therapeutic approach for advanced prostate cancer, specifically targeting castration-resistant prostate cancer (CRPC) that has developed resistance to enzalutamide treatment. The research investigates the role of...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Virginia a $192,887 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on May 8, 2026, with completion targeted for April 30, 2029. This award supports biomedical research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. The grant funds research into sphingolipid-guided stratification and therapeutic opportunities...
- Federal Project Grant Award Summary Virginia Commonwealth University received a $403,586 Project Grant from the National Cancer Institute (Cancer Biology Research program, CFDA 93.396) beginning August 1, 2025, and concluding July 31, 2027. The award supports research to develop codon-specific isotope labeling technology for nuclear magnetic resonance (NMR) resonance assignment. This novel methodology addresses critical obstacles in characterizing intrinsically disordered proteins (IDPs),...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Virginia a $161,500 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, with completion targeted for May 31, 2028. This research initiative develops innovative methodologies for classifying heterogeneous circulating tumor cells (CTCs) from pancreatic ductal adenocarcinoma (PDAC) patients by leveraging single-cell deformability as a complementary metric to traditional...
- Federal Grant Award Summary The University of Virginia received a $2.66 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded September 1, 2025, through August 31, 2030. The award supports a coordinated research initiative to develop ceramide-directed therapeutics for acute myeloid leukemia (AML) treatment. The program integrates three inter-related research projects and four essential core facilities to define the biological...
- Federal Project Grant Summary Virginia Commonwealth University received a $399,187 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded May 7, 2026, with completion targeted for April 30, 2028. The grant supports translational research investigating glycosaminoglycans (GAGs)—specifically heparan sulfate and chondroitin sulfate—as a theragnostic approach to overcome platinum resistance in gynecological malignancies, particularly clear...
- Summary of Federal Project Grant Award The University of Pittsburgh received a $261,662 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective December 1, 2025, with a completion date of April 16, 2029. This award funds an integrated in silico and in vivo genetic screening research project designed to identify subtype-specific genetic dependencies in hepatocellular carcinoma (HCC). The project applies deep learning computational...
- Federal Grant Award Summary The National Cancer Institute awarded a $2.49M Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research, effective August 1, 2025, through July 31, 2030. This research initiative comprises three integrated projects investigating lipid metabolism as a determinant of ferroptosis sensitivity in cancer cells. Project 1, led by Dr. Xuejun Jiang at Memorial Sloan Kettering Cancer Institute, examines how...
- Federal Grant Award Summary Virginia Commonwealth University received a $208,311 Project Grant award dated September 12, 2025, from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859) to conduct fundamental biomedical research examining the role of C18-ceramide in iron-dependent cell death. The project, titled "C18-Ceramide as an Essential Factor in Iron Dependent Cell Death," will be conducted in Virginia through...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a $501,422 Project Grant under the Cancer Biology Research program (CFDA 93.396) commencing May 1, 2026, with completion targeted for April 30, 2031. This award supports fundamental research to advance understanding of synthetic lethal (SL) vulnerabilities in specific cancer subtypes, with the ultimate objective of developing novel precision oncology therapeutics. The research...